Project Grant R01EY036910
Award Date
5/1/25
Completion Date
4/30/29
Dollars Obligated
$679K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award, funded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), supports research to establish the molecular, cellular, and transcriptional mechanisms that regulate reactive astrocyte phenotypes in the optic nerve head and Müller glia, and their impact on retinal ganglion cell survival in a mouse model of glaucoma. The $1,130,220 award, with a project period from September 1, 2024 to April 30, 2029, will utilize state-of-the-art single cell...
This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), provides $246,000.00 to The University of Texas Southwestern Medical Center to conduct research aimed at identifying and characterizing gene/protein defects and molecular pathways that lead to early-onset glaucoma. The researchers will employ a forward genetics approach, utilizing high-throughput screening of randomly generated mutations in mice to uncover novel gene-phenotype...
The National Eye Institute (NEI) awarded a Project Grant (CFDA 93.867 - Vision Research) totaling $234,000.00 to Oregon Health & Science University (OHSU) to research enhancing stem cell restoration of intraocular pressure (IOP) homeostasis through senolytic treatments for glaucoma. The project aims to use senolytics and senoreverters to restore IOP homeostatic function in glaucomatous tissue, with or without the assistance of stem cell transplantation. This research has the potential to...
This National Eye Institute (NEI) Project Grant award, under CFDA Program 93.867 - Vision Research, is providing $526,841 to Vanderbilt University Medical Center (VUMC) to investigate the role of cGMP signaling in glaucomatous neurodegeneration. The project aims to elucidate how disrupted cGMP signaling in glaucoma impacts retinal astrocyte-vascular networks, leading to retinal ganglion cell (RGC) metabolic stress and subsequent axon degeneration. The research will utilize cell-specific...
This $185,000 Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports research to discover novel disease-modifying therapies for the prevention and treatment of glaucoma. The principal investigators, Dr. Abbot F. Clark and Dr. David P. Siderovski from the University of North Texas Health Science Center (UNTHSC), will use computational and experimental approaches to identify small molecule inhibitors that can interfere with the...
This $460,625 federal Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports research to investigate the underlying cellular and synaptic mechanisms that explain changes in retinal ganglion cell (RGC) activity following optic nerve injury. The two-year project, awarded to Yale University, aims to determine how different types of RGC are impacted by increased intraocular pressure or direct optic nerve crush, and to validate methods for...
This $715,098 project grant, awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), aims to enhance glaucoma risk prediction through advanced genomics and machine learning. The Massachusetts Eye and Ear Infirmary, a renowned non-profit hospital and research center affiliated with Harvard Medical School, will lead this 5-year effort. The project has three key objectives: 1) Improve polygenic risk score (PRS) performance for glaucoma by leveraging natural...
This Project Grant award of $618,088.00 from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), supports research on the role of mitochondrial DNA (mtDNA) and the DNA/RNA sensor ZBP1 in retinal neurodegeneration associated with glaucoma. The multi-PI research team will utilize novel ZBP1 conditional knockout or overexpression mouse models, in vivo tracking of extracellular vesicles, and comprehensive in vitro mechanistic studies to test the hypothesis that damaged...
This Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports research to optimize lead compounds, determine their mechanism of action, and provide additional data to support their development as topically administered therapeutics for the treatment of primary open-angle glaucoma (POAG) and steroid-induced glaucoma. The $617,323 award, effective from July 1, 2024 to June 30, 2028, will enable the University of Notre Dame DU Lac to conduct...
The National Eye Institute (NEI) awarded a $191,095 Project Grant (CFDA 93.867 Vision Research) to the University of North Texas Health Science Center (UNTHSC) to investigate metabolic changes in the optic nerve head that contribute to fibrosis and retinal ganglion cell axon loss in glaucoma. The research aims to establish that glutaminolysis, regulated by the YAP/TAZ transcriptional coactivators, drives the fibrotic response in astrocytes and lamina cribrosa cells under glaucoma-associated...